| ［1］ |
Di Cesare A, Di Meglio P, Nestle FO. The IL⁃23/Th17 axis in the immunopathogenesis of psoriasis［J］. J Invest Dermatol, 2009,129（6）:1339⁃1350. doi: 10.1038/jid.2009.59.
|
| ［2］ |
Tang H, Jin X, Li Y, et al. A large⁃scale screen for coding variants predisposing to psoriasis［J］. Nat Genet, 2014,46（1）:45⁃50. doi: 10.1038/ng.2827.
|
| ［3］ |
Girolomoni G, Strohal R, Puig L, et al. The role of IL⁃23 and the IL⁃23/TH 17 immune axis in the pathogenesis and treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（10）:1616⁃1626. doi: 10.1111/jdv.14433.
|
| ［4］ |
Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL⁃17A⁃producing cells and are found in lesional skin［J］. J Invest Dermatol, 2011,131（9）:1853⁃1860. doi: 10.1038/jid.2011.139.
|
| ［5］ |
Clark RA. Resident memory T cells in human health and disease［J］. Sci Transl Med, 2015,7（269）:269rv1. doi: 10.1126/scitranslmed.3010641.
|
| ［6］ |
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
|
| ［7］ |
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
|
| ［8］ |
Griffiths C, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate⁃to⁃severe psoriasis: results from VOYAGE 1［J］. J Dermatolog Treat, 2020:1⁃9［2021⁃02⁃19］. https://www.tandfonline.com/doi/full/10.1080/09546634.2020. 1782817. doi: 10.1080/09546634.2020.1782817.
|
| ［9］ |
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
|
| ［10］ |
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate⁃to⁃severe plaque psoriasis: a 1 year real⁃life study［J］. J Clin Med, 2020,9（7）:2170. doi: 10.3390/jcm9072170.
|
| ［11］ |
Maliyar K, O′Toole A, Gooderham MJ. Long⁃term single center experience in treating plaque psoriasis with guselkumab［J］. J Cutan Med Surg, 2020,24（6）:588⁃595. doi: 10.1177/120347542 0932514.
|
| ［12］ |
Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL⁃23⁃regulated IL⁃17 and IL⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid. 2019.05.016.
|
| ［13］ |
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phase III NAVIGATE trial［J］. Br J Dermatol, 2018,178（1）:114⁃123. doi: 10.1111/bjd.15750.
|
| ［14］ |
Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti⁃interleukin⁃17 treatment: a real⁃life 52⁃week retrospective study［J］. Dermatol Ther, 2021,34（1）:e14673. doi: 10.1111/dth.14673.
|
| ［15］ |
Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non⁃Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2［J］. J Dermatol, 2019,46（12）:1141⁃1152. doi: 10.1111/1346⁃8138. 15109.
|
| ［16］ |
Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, for the treatment of moderate to severe plaque⁃type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol, 2018,45（9）:1053⁃1062. doi: 10.1111/1346⁃8138.14504.
|
| ［17］ |
Yeremenko N, Paramarta JE, Baeten D. The interleukin⁃23/interleukin⁃17 immune axis as a promising new target in the treatment of spondyloarthritis［J］. Curr Opin Rheumatol, 2014,26（4）:361⁃370. doi: 10.1097/BOR.0000000000000069.
|
| ［18］ |
Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
|
| ［19］ |
Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4.
|
| ［20］ |
Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study［J］. J Dermatol, 2018,45（5）:529⁃539. doi: 10.1111/1346⁃8138.14294.
|
| ［21］ |
Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. doi: 10.1001/jamadermatol. 2017.5937.
|
| ［22］ |
Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
|
| ［23］ |
Puig L, Tsai TF, Bhutani T, et al. Safety in moderate⁃to⁃severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti⁃tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1744⁃1749. doi: 10.1111/jdv.16460.
|
